Alpha Cognition's ZUNVEYL Sales Reach $6.8M in FY25

Got story updates? Submit your updates here. ›

Alpha Cognition Inc. (NASDAQ: ACOG) reported strong FY25 sales of $10.2M for its Alzheimer's drug ZUNVEYL, including $6.8M in direct product revenue. The company saw a 62% quarter-over-quarter increase in bottles dispensed, reaching a record 1,859 in December, as repeat orders from 729 homes and 865 prescribers supported the drug's growing adoption in long-term care facilities.

Why it matters

Alpha Cognition's ability to drive durable adoption of ZUNVEYL in the long-term care market is a key indicator of the drug's commercial potential. Repeat business from facilities and prescribers suggests the drug is becoming embedded in treatment protocols, which could lead to sustainable revenue growth.

The details

In the fourth quarter of 2025, Alpha Cognition reported $2.5M in ZUNVEYL net product revenue, a 62% increase in bottles dispensed quarter-over-quarter to 4,941 units. The company ended the full fiscal year 2025 with $10.2M in total revenue, including $6.8M from ZUNVEYL sales. Importantly, 82% of the 729 ordering homes were repeat customers, and 69% of the 865 prescribers had written repeat orders, indicating growing acceptance of the drug within long-term care facilities.

• In Q4 2025, ZUNVEYL net product revenue reached $2.5M.
• In FY 2025, ZUNVEYL sales totaled $6.8M out of $10.2M in total revenue.
• In Q4 2025, bottles dispensed increased 62% quarter-over-quarter to 4,941 units.
• In December 2025, a record 1,859 ZUNVEYL bottles were dispensed.

What’s next

Alpha Cognition expects continued sequential sales growth for ZUNVEYL in 2026 as it remains funded with $66M in cash to keep scaling commercialization efforts.